After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO

Intuit's stock took a 9% dive in after-hours trading due to a disappointing Q4 earnings report and cautious guidance. The company reported EPS of $2.50, falling short of analysts' consensus of $3.54. Revenue reached $4.4 billion, surpassing estimates of $4.28 billion. The primary concern stemmed from Intuit's conservative full-year 2027 guidance, projecting EPS of $22.88–$23.12 and revenue of $23.3–$23.5 billion, which trailed Wall Street's expectations.

Semtech experienced a 3% rise after delivering impressive Q2 results. The semiconductor supplier reported adjusted EPS of $0.71 on $341.9 million in revenue, exceeding analysts' expectations. Semtech's strong performance was driven by a remarkable 64% growth in its AI data center networking segment. Management presented optimistic Q3 guidance, anticipating revenue between $405–$415 million and EPS of $1.02–$1.08.

Spyre Therapeutics faced a 16% drop following the release of underwhelming clinical trial results. The biotechnology company's Phase 2 SKYWAY trial, evaluating SPY072 (a TL1A inhibitor) for rheumatoid arthritis, failed to meet its internal efficacy standards for progression as a monotherapy. Despite a modest Q2 beat-and-raise report, Zoom stock declined by 3.5%.

The video communications provider reported EPS of $1.55 on $1.28 billion in revenue and increased its full-year fiscal 2027 revenue guidance to $5.09–$5.10 billion. Profit-taking occurred as persistent growth normalization in Zoom's core online segment continues to hinder significant valuation expansion. nCino experienced a 10% decline after unveiling its Q2 results.

While the cloud banking platform reported adjusted EPS of $0.05 on $161 million in revenue, investors reacted negatively to a modest Q3 revenue outlook of $161.25–$163.25 million, raising concerns about prolonged sales cycles within regional banking clients.